Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial

Rawstron, A., Webster, N., Dalal, S. et al. (15 more authors) (2023) Using Peripheral Blood (PB) Measurable Residual Disease (MRD) Levels to Predict <0.01% Bone Marrow Disease (BM uMRD4): Identification of Effective PB Targets for CLL Treatment Cessation in the Ibrutinib+Venetoclax Arm of the FLAIR Trial. [Conference abstract]

Metadata

Item Type: Conference abstract
Authors/Creators:
  • Rawstron, A.
  • Webster, N.
  • Dalal, S.
  • de Tute, R.M.
  • Bell, S.
  • Cairns, D.A. ORCID logo https://orcid.org/0000-0002-2338-0179
  • Girvan, S.
  • Greatorex, N.
  • Hockaday, A.
  • Jackson, S.
  • Phillips, D.
  • Stones, D.
  • Allsup, D.
  • Bloor, A.J.C.
  • Sarma, A.
  • Varghese, A.M.
  • Munir, T.
  • Hillmen, P.
Copyright, Publisher and Additional Information:

© 2023 The American Society of Hematology. Published by Elsevier. Reproduced in accordance with the publisher's self-archiving policy.
Dates:
  • Published (online): 2 November 2023
  • Published: 29 November 2023
  • Published:
Institution: The University of Leeds
Academic Units: The University of Leeds > Faculty of Medicine and Health (Leeds) > School of Medicine (Leeds) > Inst of Clinical Trials Research (LICTR) (Leeds)
Funding Information:
Funder
Grant number
Cancer Research UK Supplier No: 138573
CTUQQR-Dec22/100002
Date Deposited: 15 Mar 2024 12:04
Last Modified: 07 Mar 2026 02:19
Status: Published
Publisher: American Society of Hematology
Identification Number: 10.1182/blood-2023-187943
Open Archives Initiative ID (OAI ID):

Export

Statistics

View Altmetric information about this item.


CORE (COnnecting REpositories)